Ramandeep Rattan

Ramandeep Rattan, PhD.
Adjunct Assistant Professor
Department of Oncology
Wayne State School of Medicine
Assistant Scientist
Women’s Health Services
Henry Ford Hospital

Research Interests

  1. Adipocyte-ovarian cancer interaction
  2. Metabolism of ovarian cancer
  3. AMPK in ovarian cancer

Research description:
The Rattan lab is centered on translational ovarian cancer research, the most lethal of gynecologic malignancies.  The main areas of interest include:

  1. Elucidation and therapeutic targeting of adipose tissue and ovarian cancer interactions. Adipocytes have recently been shown to play an integral role in promotion and spread of ovarian cancer. We are interested in studying the uptake and signaling talk that occurs between the fatty acids released by the adipocytes and ovarian cancer cells, through understanding the role of novel free fatty acid receptors.
  2. Dissecting the metabolic differences between chemo-sensitive and -resistant ovarian tumors. We have found methionine metabolism to be altered in platinum resistant ovarian cancer cells. Currently we are investigating the specific metabolites or sub-pathway that could play a role in mediating chemo-resistance and to use these differences to find a potential therapeutic target unique to chemo-resistant cancer cells.
  3. Role of the metabolic enzyme AMPK in ovarian cancer. AMPK (AMP-activated kinase) is a master regulator of metabolism in all living beings. It is activated by the anti-diabetic drug metformin, which is been extensively studied as a repurposed drug for treatment of various cancers, including ovarian. We have published metformin’s ability to inhibit ovarian tumors in vitro and in vivo. We are currently studying the pathological role of AMPK in ovarian cancer using AMPK knockout mice.

Recent  Publication:

Al-Wahab Z, Mert I,Tebbe C, Chhina J, Hijaz M, Morris R, Ali-Fehmi R, Giri S, Munkarah A and Rattan R*. Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction. Oncotarget.2015;6:10908-23.

Poisson L, Munkarah A, Madi H,  Datta I, Hensley-Alford S, Tebbe C, Buekers  T, Giri S and Rattan R*. A metabolomic approach to identifying platinum 3 resistance in ovarian cancer. J of Ovarian Res. 2015:8:13.

Al-Wahab Z, Tebbe C, Chhina J, Dar S, Morris R, Giri S, Munkarah A and Rattan R*. Dietary energy balance modulates ovarian cancer progression and metastasis. Al-Wahab Z, Tebbe C, Chhina J, Dar SA, Morris RT, Ali-Fehmi R, Giri S, Munkarah A, Rattan R*. Oncotarget. 2014;5:6063-75.

Tebbe C, Chhina J, Dar S, Sarigiannis K, Giri S, Munkarah A and Rattan R*. Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget. 2014;5:4746-64

Kumar S, Meuter A, Langstraat C, Giri S, J. Chien,  Rattan R, Cliby W, Rattan R,  Shridhar V. A case control study of metformin in ovarian cancer. Cancer  2013;9:555-62.

Rattan R*, Ali-Fehmi R and Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J of Oncology, 2012;2012:928127.

Postdoctoral training (2006-2011), Mayo Clinic, Rochester, MN
PhD (2005), Medical University of South Carolina, Charleston, SC
MS (1999), Central Research Institute, India
BSc (1996), PGIMER, India